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THE NEED TO REEXAMINE GINA: A CALL FOR A
BUSINESS NECESSITY EXCEPTION TO THE
GENETIC INFORMATION NONDISCRIMINATION
ACT
Alyson Horn*
INTRODUCTION
With the passage of the Genetic Information Nondiscrimination Act
(GINA or the Act) in 2008, it became a violation of federal law for
employers to discriminate against employees or job applicants based on their
genetic information.1 The Act prohibits employers from using genetic
information in employment decisions and places restrictions on employers
requesting or requiring genetic information as a condition of employment.
Similar to the way in which the Americans with Disabilities Act (ADA)
prevents employers from discriminating against employees on the basis of
disabilities,2 GINA seeks to offer protection to individuals who may suffer
discrimination on the basis of a genetic predisposition for a particular
disease or condition. While it offers a limited number of exceptions, GINA
does not offer a business necessity exception as found under the ADA.3
This Note argues that GINA is too limited and that there are certain
workplace situations that necessitate a business necessity exception, or,
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1. Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff-1
(2008).
2. Americans with Disabilities Act of 1990, 42 U.S.C. §§ 12101-12103, 1211112117 (2006).
3. Under the ADA, a business necessity exception allows employers to use
qualification standards or other selection or screening criteria that exclude, or tend to
exclude, an individual or a class of individuals with a disability because of their disability
when the standards or criteria relate to an essential function of the job and a reasonable
accommodation is not possible. 29 C.F.R. § 1630.10 (2011). The concept of business
necessity is explained in greater detail in section II.A. of this Note.
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alternatively, an exception for when there is a direct threat to health and
safety. There is a particular need for such an exception in non-traditional
work environments such as those faced by employees of the State
Department, Peace Corps, and civilians in the Department of Defense
(DOD). While soldiers who are deployed to zones where malaria is
prevalent (such as Afghanistan) are subject to glucose-6-phosphate
dehydrogenase (G6PD) testing, the passage of GINA could now prevent
similar testing of civilian Federal employees.4 A G6PD deficiency can
produce a hematologic disorder, specifically hemolytic anemia, which can
be seriously aggravated by primaquine, a medication routinely given to those
who are in areas prone to malaria infections.5 If employees of the Foreign
Service, Agency for International Development (USAID), and Peace Corps
(who may be sent to many malaria-ridden regions of the world) cannot
lawfully be tested for a G6PD deficiency, their health may be put at serious
risk.
Though decisions about military deployments for uniformed personnel
can be informed by the results of this testing, civilian employees could
potentially be prevented from obtaining the benefit from such preventive
measures due to the restrictions imposed by GINA.6 The potential for
serious medical complications for a G6PD-deficient employee given
primaquine is a perfect example of a situation in which there is a clear
benefit to amending GINA. This Note advocates for the inclusion of a
business necessity exception to the Act, proposing that the potential lifesaving consequences far outweigh the privacy and discrimination concerns
that were the driving forces behind the Act.
Section I of this Note begins with a discussion of the recent advances
made in the world of genetics and the corresponding rise in the fear of
potential discrimination based on a person’s genetic predisposition for a
disease or condition. Section II provides an overview of the legal options
	
  
4. Clinton K. Murray, et al., Prevalence of Glucose-6-Phosphate Dehydrogenase
Deficiency in U.S. Army Personnel, 171 MIL. MED. 905, 905 (2006).
5. Ernst Beutler, Glucose-6-Phosphate Dehydrogenase Deficiency: A Historical
Perspective, 111 BLOOD J. 16, 16-17 (Jan. 2008), available at http://bloodjournal.
hematologylibrary.org/content/111/1/16.full.pdf.
6. Compare Susannah Baruch & Kathy Hudson, Civilian and Military Genetics:
Nondiscrimination Policy in a Post-GINA World, 83 AM. J. HUM. GENETICS 435, 437
(2008) (stating that GINA does not apply to members of the United States Military, to
veterans obtaining healthcare through the Department of Veterans Affairs, or to the
Indian Health Service); see also the Act’s definition of “employee,” 42 U.S.C.
2000ff(2)(A) (2008) (referring to the definition provided in 42 U.S.C. 2000e(f), which
states that an employee “means an individual employed by an employer” and “include[s]
employees subject to the civil service laws of a State government, governmental agency
or political subdivision”).
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considered to be potential shields against genetic discrimination, including
the ADA, judicial interpretations, and Executive Order 13145. A description
of the major elements of GINA is then provided in Section III of this Note,
including a brief discussion of the Act’s legislative intent. Section IV delves
more deeply into the why a business necessity exception is necessary, and
begins with a brief medical overview of G6PD deficiency. While no cases
have gone to litigation on this matter, this Section also offers a case study of
genetic discrimination in an employment claim made by a Peace Corps
applicant who was denied placement in a malarial zone due to his G6PD
deficiency. Finally, turning to the potential negative consequences that may
arise out of the disparate treatment of uniformed versus civilian employees
with regards to G6PD testing, the facts are combined to make a case for a
business necessity exception to GINA in order to ensure the safety of
employees in the workplace.

I. ADVANCES IN GENETIC KNOWLEDGE AND THE RESULTING FEAR OF
DISCRIMINATION
It is now widely known and accepted that the functioning of most living
organisms is determined by the chemical compound Deoxyribonucleic acid
(DNA).7 However, more than half a century ago scientists knew very little
about the connection between genetics and disease.8 Giant leaps in scientific
discovery took place between 1953, when James Watson and Francis Crick
first described the double helix structure of DNA9 and 1990, when the
National Institutes of Health and the Department of Energy collaborated
with international partners on what is known as the Human Genome
Project.10 The ambitious goal of this Project was to sequence the 3 billion
base letters found in the complete set of DNA in the human body called the
human genome.11 Finished in 2003, the ultimate aim of the study was to
serve as a resource for a wide range of biomedical research, including the

	
  
7. A Brief Guide to Genomics: DNA, Genes and Genomes, NAT’L HUM. GENOME
RES. INST., NAT’L INSTS. HEALTH (last updated Apr. 14, 2014),
http://www.genome.gov/18016863 (explaining that every DNA strand is comprised of
four chemical units, called nucleotide bases, which comprise the genetic “alphabet.” The
bases are “adenine (A), thymine (T), guanine (G), and cytosine (C)”).
8. NAT’L INSTS. HEALTH, HUMAN GENOME PROJECT FACT SHEET 1 (last updated
Oct. 2010), http://report.nih.gov/NIHfactsheets/Pdfs/HumanGenomeProject(NHGRI).pdf.
9. Id.
10. Id.
11. Id. The fact sheet compares the possession of a complete sequence of the human
genome to having all required pages to a manual needed to make the human body. It is
the interpretation of this newly discovered content of these pages that is identified as the
next challenge. Id.
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genetic variants that increase chances for the development of specific types
of diseases, how the genome works and the genetic basis for health and
disease.12 Due to the work of the Human Genome Project, researchers have
discovered more than 1,800 disease genes and now have the ability to find a
gene suspected of causing an inherited disease in a matter of days, rather
than the years it took previously.13 At present, less than ten years after the
Project’s completion, the process of genetic sequencing is much faster and a
great deal less costly, and some predict we are not too far off from the
$1,000 genome.14

A. The Current State of Genetic Testing
More than 2,000 tests have been developed to detect a large number of
genetic conditions, enabling patients to learn their risks for diseases and
assisting doctors with a more accurate diagnosis.15 The process of genetic
testing gathers cells from an individual through various means including
from samples of blood, “saliva, the inside of the cheek, or any other
tissue.”16 While a positive test result for certain genetic mutations is nearly
determinative of the possibility of manifesting that disorder, like the test for
Huntington’s Disease, genetic tests for other conditions like breast cancer,
cystic fibrosis and Alzheimer’s Disease are less than certain.17 However, the
	
  
12. A Brief Guide to Genomics: DNA, Genes and Genomes, supra, note 7.
13. HUMAN GENOME PROJECT FACT SHEET, supra note 8, at 1.
14. As Genetic Sequencing Spreads, Excitement, Worries Grow, NAT’L PUB. RADIO
(Sept. 18, 2012, 3:34 AM), http://www.npr.org/templates/transcript/transcript
.php?storyId=160958948 (statement by NPR’s Rob Stein, stating that the current cost per
individual gene sequencing is approximately $4,000); see also Eryn Brown, What a
$1,000 Genome Could Mean for Medicine, L.A. TIMES
(Jan. 10, 2012),
http://articles.latimes.com/2012/jan/10/news/la-heb-1000-dollar-genome-20120110
(explaining that biotechnology firms have been on the quest to offer machines capable of
sequencing a human genome in about one day at a cost of approximately $1,000, with the
idea that the price drop will enable doctor’s to provide a more “personalized medicine”
for more accurate patient diagnosis and care).
15. HUMAN GENOME PROJECT FACT SHEET, supra note 8; see also A Brief Guide to
Genomics: DNA, Genes and Genomes, supra note 7 (noting that genome-based research
is enabling medical researchers “to develop more effective diagnostic tools, to better
understand the health needs of people based on their individual genetic make-ups, and to
design new treatments for disease”).
16. Paul Steven Miller, Is there a Pink Slip in My Genes? Genetic Discrimination in
the Workplace, 3 J. HEALTH CARE L. & POL’Y 225, 229-30 (2000).
17. Id. at 230-31 (stating that while a person who tests positive for the Huntington’s
Disease gene will develop the disease by middle age with a “chilling certainty,” a woman
who tests positive for a type of gene mutation known as the BRCA 1 mutation will have
an eighty percent chance of developing breast cancer if there is a clear history of breast
cancer in her family). Tests can additionally be used to identify carriers of certain types
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common misperception is that genetic testing offers a completely accurate
prediction as to whether an individual will manifest a genetic disease or
condition that could lead to discrimination.18

B. Fear Engendered by Newly Available Genetic Information
Unfortunately, history has proven that the specter of genetic
discrimination is a real concern.19 For example, out of the mistaken belief
that heredity was the cause of criminality, mental conditions and pauperism,
Indiana passed the first state eugenic law in 1907, mandating forced
sterilizations.20 The U.S. Supreme Court soon after sanctioned this type of
practice in its 1927 decision, Buck v. Bell, holding that states could
involuntarily sterilize individuals based on their so-called flawed genetics.21
In discussing Carrie Buck, who like her mother, was committed to the
Virginia State Colony for Epileptics and Feeble Minded, Justice Holmes
rationalized the holding by stating that, “[t]hree generations of imbeciles are
enough.”22 Even as recently as the 1970s, state legislatures enacted
mandatory screening laws with the goal of identifying those with sickle cell
anemia with the hope of reducing the incidence of the disease.23 The fact

	
  
of disease or conditions. Carriers may never actually develop the disease, but may still
possess the recessive genes and pass them onto their children who may go on to develop
the condition. Id. at 229.
18. Id. at 232 (explaining that there are a variety of factors at play beyond a genetic
disposition for the disease, that influence its severity, the timing of its onset, and
ultimately, whether the disease will ever actually manifest itself at all).
19. Statement on Genetic Discrimination in Health Insurance, AM. ASS’N FOR THE
ADVANCEMENT OF SCI., http://www.aaas.org/page/statement-genetic-discriminationhealth-insurance (last visited Mar. 26, 2014).
20. Lutz Kaelber, Eugenics/Eugenic Sterilization in Indiana, U. VT.,
http://www.uvm.edu/~lkaelber/eugenics/IN/IN.html (last visited Mar. 26, 2014).
21. Jessica L. Roberts, The Genetic Information Nondiscrimination Act as an
Antidiscrimination Law, 86 NOTRE DAME L. R. 597, 608 (2011).
22. Buck v. Bell, 274 U.S. 200, 207 (1927) (justifying decision by stating that forced
sterilization is a better societal solution than the alternative which would involve “waiting
to execute degenerate offspring for crime [or letting] them starve for their imbecility”).
23. Genetic Screening and Discrimination: Relevance of Historical Experience,
NAT’L HUM. GENOME RES. INST., NAT’L INSTS. HEALTH, http://www.genome.gov/
25019904 (last updated Apr. 2, 2012) (explaining that an inadequate level of education
and counseling led to confusion about the sickle cell trait and actual sickle cell disease).
Sickle cell anemia is the most common form of sickle cell disease and the disorder causes
the normally doughnut-shaped red blood cells to resemble a crescent, or “sickle.” The
abnormally shaped cells die at a much faster rate than they can be replaced, and those
suffering from the condition can experience chronic pain and/or fatigue. What is Sickle
Cell Anemia, NAT’L HEART, LUNG, & BLOOD INST., NAT’L INSTS. HEALTH,
http://www.nhlbi.nih.gov/health/health-topics/topics/sca/ (last visited Nov. 14, 2012).
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that African Americans were disproportionately affected, along with the
inadequate privacy measures with regards to the results of these tests, gave
rise to a legitimate fear in lawmakers that there was a real possibility this
would lead to discrimination in employment.24 Ultimately, Congress passed
the National Sickle Cell Anemia Control Act in 1972, which withheld
federal funding from those states that utilized mandatory testing.25
While the past few decades have been an extremely exciting time in
scientific discovery, it is nonetheless unsurprising that many individuals
have grown concerned about the possibility of genetic discrimination.26 For
example, from 2001-2003, over 86,000 adults were surveyed about their
willingness to undergo genetic testing, and forty percent of the participants
revealed they did not believe such testing was a good idea, mostly due to
fear of losing insurance coverage.27 Similarly, results in several studies
conducted by the Genetics and Public Policy Center at Johns Hopkins
University showed an increasingly high level of public concern about an
employer having access to genetic information, rising from eighty-six
percent in 2002 to ninety-two percent in 2004.28 These concerns extend to
health care professionals as well, with one study showing that 108 of 159 of
genetic counselors29 would not submit charges for genetic tests to insurance
companies out of fear of possible discrimination.30 Even more worrisome
were those studies showing that individuals were deciding to forgo genetic

	
  
24. Baruch & Hudson, supra note 6, at 436; Melinda B. Kaufmann, Genetic
Discrimination in the Workplace: An Overview of Existing Protections, 30 LOY. U. CHI.
L.J. 393, 402-03.
25. Ingrid Lobo, Genetic Testing, SCITABLE BY NATURE EDUC., NATURE,
http://www.nature.com/scitable/spotlight/genetic-testing-13782065 (last visited Apr. 14,
2014); National Sickle Cell Control Act of 1972, Pub. L. No. 92-294, 86 Stat. 136.
26. Louise McIntosh Slaughter, Genetic Testing and Discrimination: How Private Is
Your Information? 17 STAN. L. & POL’Y REV. 67, 70-71 (2006).
27. Id. at 71 (explaining that this type of reluctance is detrimental to America’s
public health and the potential future benefits of scientific research).
28. Id.
29. Genetic counseling is described as:
[T]he professional interaction between a healthcare provider with specialized
knowledge of genetics and an individual or family. The genetic counselor
determines whether a condition in the family may be genetic . . . [whether]
another relative may be affected . . . and offer[s] and interpret[s] genetic tests
that may help eliminate risk of disease.
Genetic Counseling, Talking Glossary of Genetic Terms, NAT’L HUMAN GENOME RES.
INST., NAT’L INSTS. HEALTH, http://www.genome.gov/Glossary/index.cfm?id=79 (last
visited Nov.12, 2012).
30. Slaughter, supra note 26, at 71.
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testing altogether due to the potential for discrimination, even if the early
detection of a genetic mutation could help in preventing an early death.31	
  

II. LEGAL OPTIONS PRIOR TO GINA
A. The Americans with Disabilities Act (1990)
Out of this concern for possible discriminatory use of genetic information
arose a search for legislative guidance on the issue. In offering protection
against discrimination based on disabilities, the ADA was viewed as a
possible shield against genetic discrimination.32 Enacted in 1990, the ADA
was the Congressional response to the growing concern that people with
disabilities were facing discrimination and a lack of employment
opportunities.33 After its passage, an employer was no longer able to make a
request for medical information prior to extending an offer of employment.34
After an offer of employment has been made, however, an employer may
conduct or request a medical examination to determine whether the
employee may perform the essential functions of the job.35 If required, the
exam must be given to all entering employees and the employer must
demonstrate that the reason for the exam is both job-related and consistent
with business necessity.36 Based on the results of these pre-employment
exams, the employer is permitted to screen out those with disabilities who
cannot meet qualification standards or who cannot perform the essential
functions of the job even with reasonable accommodation.37 Furthermore,
the employer is permitted to screen out those who would pose a “direct
threat to the health or safety of other individuals in the workplace.”38 The
ADA defines “direct threat” in the statute as “a significant risk to the health
	
  
31. Slaughter, supra note 26, at 71 (outlining further that twenty-five percent of
respondents said they would use an alias to obtain a genetic test while sixty percent
indicated they would not share the information with a colleague out of privacy concerns
and fear of discrimination).
32. U.S. EEOC, Notice No. 915.002, Policy Guidance on Executive Order 13,145:
To Prohibit Discrimination in Federal Employment Based on Genetic Information (July
26, 2000), available at 2000 WL 33407180.
33. Americans with Disabilities Act of 1990, 42 U.S.C. §§ 12101-12113 (2000); see
also Nicole Silvestri, Echazabal and the Threat to Self-Defense: The Most Recent Call
for a Consistent, Interstate Genetic Non-Discrimination Policy, 7 U. PA. J. LAB. & EMP.
L. 409, 413 (2005) (describing the ADA as one of the first “empowering pieces of
disability legislation”).
34. 42 U.S.C. § 12112(d)(2)(A) (2000).
35. Id. at § 12112(d)(4)(A).
36. Id. at § 12112(d)(3)-(4)(A).
37. Id. at § 12112(b)(5)(A).
38. 42 U.S.C. § 12113(b).
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or safety of others that cannot be eliminated by reasonable
accommodation.”39 The Equal Employment Opportunity Commission
(EEOC) regulations expanded the statutory definition to include a threat-toself situation,40 an expansion upheld by the Supreme Court in Chevron USA
Inc. v. Echazabal.41 In this case, Echazabal, a long-time oil refinery worker,
brought suit when his offer of employment from Chevron was revoked after
he failed a required medical exam showing that he had asymptomatic,
chronic active hepatitis C.42 The Court clarified that a direct threat is one
that is “made on the basis of individualized risk assessments,” and upheld
Chevron’s decision to withdraw the offer on the basis that exposure to
solvents and chemical in the oil refinery process could worsen his condition,
or in other words, that it would be a threat to the employee himself.43
In Bragdon v. Abbot, the Supreme Court addressed the idea that the ADA
also covers discrimination for a condition that has not yet manifested itself
by demonstrating actual physical symptoms.44 In this case, the plaintiff
brought suit against her dentist for his refusal to fill a cavity due to her HIV
positive status.45 Though her condition had not manifested itself as fullblown AIDS, the Court found that someone infected with HIV qualified as
“disabled” under the ADA since it “substantially limits” life activities.46
Justice Rehnquist urged caution in his partial dissent, however, arguing that
if “taken to its logical extreme [the majority opinion] would render every

	
  
39. Id.
40. 29 C.F.R. § 1630.2.
41. Silvestri, supra note 33, at 422 (explaining that this more expansive definition
was first put forward by the EEOC in its interpretation of the statutory language of the
ADA); see also Chevron USA Inc. v. Echazabal, 536 U.S. 73, 81-82 (2002) (concluding
that the Congressional omission of the threat-to-self-language does not preclude it from
being included in a more expansive understanding of legislative intent).
42. Silvestri, supra note 33, at 422-23. Echazabal was tested each of the two times
he applied for a position with the company and the exams showed liver abnormality
and/or function. The cause was later determined to be from Hepatitis C. Chevron, 536
U.S. at 76.
43. Chevron, 536 U.S. at 86 (clarifying that the defense must be “based on a
reasonable medical judgment that relies on the most current medical knowledge and/or
the best available objective evidence”).
44. Ashley M. Ellis, Genetic Justice: Discrimination by Employers and Insurance
Companies Based on Predictive Genetic Information, 34 TEX. TECH L. REV. 1071, 1086
(2003).
45. Bragdon v. Abbot, 524 U.S. 624, 628-29 (1998). The dentist stated that he was
willing to fill the cavity at the local hospital with no extra charge, however, the plaintiff
would be responsible for covering the cost of using the hospital facilities. Id. at 628.
46. Id. at 630 (clarifying that due to the immediacy of the damage to an affected
individual’s white blood cells, HIV is to be determined as “an impairment from the
moment of infection”).
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individual with a genetic marker for some debilitating disease ‘disabled’
here and now because of some future effects.”47 This dissenting argument
engendered a level of concern, for some, as to whether the ADA would, in
fact, be a meaningful tool in combating genetic discrimination.48	
  

B. Executive Order 13,145
Recognizing the lack of a comprehensive federal legislative response to
genetic discrimination, on February 8, 2000, President Clinton signed
Executive Order 13,145 to address the issue in the federal workforce.49 The
Order prohibits federal employers from using “protected genetic
information” along with information from genetic testing, including genetic
testing of family members, in employment decisions.50 This prohibition
includes using genetic information as a basis for a refusal to hire or a
decision to fire, as well as its use in depriving an employee of workplace
opportunities.51 In its limited application to those employees who work for
federal agencies, however, the Order fell short of offering a more
widespread protection against genetic discrimination.52

III. THE GENETIC INFORMATION NONDISCRIMINATION ACT (2008)
A. Legislative Intent
The “patchwork of laws and interpretations”53 on the issue of genetic
discrimination finally received a comprehensive federal legislative response

	
  
47. Id. at 661 (Rehnquist, J., concurring in part and dissenting in part) (contending
that the plaintiff was unable to demonstrate how she was “utterly unable” to engage in
those activities identified by the majority).
48. Baruch & Hudson, supra note 6, at 437.
49. Exec. Order No. 13,145, 65 Fed. Reg. 6877 (Feb. 8, 2000), reprinted as amended
in 42 U.S.C. § 2000e-16 (2003). The Executive Order states, in relevant part:
It is the policy of the Government of the United States to provide equal
employment opportunity in Federal employment for all qualified persons and
to prohibit discrimination against employees based on protected genetic
information, or information about a request for or the receipt of genetic
services. This policy of equal opportunity applies to every aspect of Federal
employment.
Id.
50. Id.
51. Id.
52. Silvestri, supra note 33, at 418.
53. Slaughter, supra note 26, at 72. Rep. Slaughter was a sponsor of GINA, first
proposing the bill in 1995. Phillip K. Vacchio & Joshua L. Wolinsky, Genetic
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with the passage of GINA in 2008.54 Hailed by former Senator Edward
Kennedy of Massachusetts as “the first major new civil rights bill of the new
century,”55 GINA offers protection from genetic discrimination by both
insurers and employers.56 It was a hard-fought, multi-year battle, with
opponents from the insurance industry and employers arguing that existing
legislation rendered the Act’s passage unnecessary and that to do so “would
only create confusion and unnecessary costs.”57 Furthermore, employers
argued that the limited number of cases brought on the subject demonstrated
that genetic discrimination was not common enough in the workplace to
warrant its own legislation.58
The situation facing Phil Hardt, a man who tested positive for the
Huntington’s Disease genetic mutation, paints the story another way.59
Confronted not just with the reality of his personal health discovery, Mr.
Hardt also had contend with the fact that his daughter was denied health
insurance due to her genetic predisposition for the disease that was
discovered as a direct result of his diagnosis.60 Congress recognized the
importance of offering comprehensive protection against genetic
discrimination for just this sort of situation, and wanted to provide a way for
the public to take advantage of the benefits of genetic testing without fear of
reprisal by insurance companies or in the workplace.61 Due to the limited
documentation of genetic discrimination occurring in the workplace, the Act
was seen as being a preemptive measure intended to circumvent a type of
discrimination that may take place in the future, not one that has existed in
recent history.62 Senator Kennedy explained that with the passage of GINA,
	
  
Information Nondiscrimination Act of 2008: It’s in Title VII’s Genes, 29 HOFSTRA LAB. &
EMP. L.J. 229, 231 (2011).
54. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, §2(5),
122 Stat. 881, 882-83.
55. Joanne Barken, Judging GINA: Does the Genetic Information Nondiscrimination
Act of 2008 Offer Adequate Protection?, 75 BROOKLYN L. REV. 545, 550 (2009).
56. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, §2(5),
122 Stat. 881, 882-83.
57. Barken, supra note 55, at 550. Passage of the bill required thirteen years of
Congressional debate as to whether there was an actual need for federal legislative
protection against genetic discrimination. It was further argued that the bill was overly
broad and would require employers to cover too wide a range of genetic disorder. Id.
58. Id. (explaining the employers also maintained that access to genetic information
in certain employment decisions was crucial, allowing them to both lower the potential
costs of future healthcare needs and to prevent paying out for excessive sick leave).
59. Vacchio & Wolinsky, supra note 53, at 232.
60. Id.
61. Id. (explaining that one of the major goals of the legislation was to provide a
standard that was both national and uniform).
62. Id.
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the door has been “open[ed] to modern medical progress for millions and
millions of Americans.”63 Indeed, the greater the number of individuals who
take advantage of genetic testing, the greater the pool of information for
researchers to use in order to perfect and refine a diagnosis based on
genetics.64	
  

B. Summary of the Law
GINA is divided into two sections and Title I focuses on health insurance,
prohibiting group health plans and health insurance providers offering group
coverage from establishing rules of eligibility or altering premium amounts
for an individual on the basis of genetic information.65 Title II focuses on
the workplace, prohibiting employers from using genetic information in
employment-related decisions, including as a justification for not hiring an
individual, a reason to discharge an employee, or with respect to
compensation or the terms and conditions of employment.66 Further, this
prohibition extends to any employer requesting that an individual undergo a
genetic test or actively seeking and purchasing genetic information about its
employees.67
GINA defines “genetic information” as information on the genetic tests of
an individual or of an individual’s family members, including information
on those family members who have already manifested a disease or
condition.68 This encompasses the request or receipt of the genetic
information of an individual, or of an individual’s family member’s genetic
information, including testing, counseling, education, and participation in
clinical research that involves genetic services.69 In practice, this definition

	
  
63. Id.
64. Id. at 233.
65. 42 U.S.C. § 300gg-53(a)-(b) (2012).
66. 42 U.S.C. § 2000ff-1(a) (2012). The statute outlines that it is unlawful for
employers:
(1) [T]o fail or refuse to hire, or to discharge, any employee, or otherwise to
discriminate against any employee with respect to the compensation, terms,
conditions, or privileges of employment of the employee, because of genetic
information with respect to the employee; or (2) to limit, segregate, or classify
the employees of the employer in any way that would deprive or tend to
deprive any employee of employment opportunities or otherwise adversely
affect the status of the employee as an employee, because of genetic
information with respect to the employee.
Id. at §§ 2000ff-1(a)(1)-(2).
67. 42 U.S.C. § 2000ff-1(b) (2012).
68. Id. at § 2000ff (4)(A) (2012).
69. Id. at § 2000ff (4)(B) (2012). “Such term includes, with respect to any
individual, any request for, or receipt of, genetic services, or participation in clinical
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would even include a company doctor from taking an employee’s family
medical history as part of a routine examination.70 While also including
genetic information about a fetus that is carried by a covered individual,71
the Act specifically excludes information pertaining to both sex and age.72
Furthermore, GINA does not offer coverage for individuals who have
manifested physical symptoms of a disease, even if it is genetically linked,
as such an instance would be covered under the protections of the ADA.73	
  
GINA does, however, provide for six very limited exceptions to this
rule.74 First, an employer is exempt from the rule’s requirements when it
inadvertently requests family medical information.75 Nor is it a violation to
receive aggregate information about employees under the following
conditions: 1) When an employer provides or sponsors a health or genetic
service or program; 2) the employee provides voluntary, written
authorization for employers to obtain family genetic information obtained
through that service; 3) only the employee and health care professional
receive individually identifiable information on those services rendered; and
4) the employer only receives information that pertains to those services that
is in the aggregate form, and does not disclose the identities of individual
participants in the employer-provided health service.76 Furthermore,
employers are authorized to request family medical information in order to
comply with the Family and Medical Leave Act of 1993.77 Employers are

	
  
research which includes genetic services, by such individual or any family member of
such individual.” Id.
70. Id. at §2000ff-1(b).
71. Id. at § 2000ff-8(b)(1) (2012).
Any reference in this chapter to genetic information concerning an individual
or family member of an individual shall—(1) with respect to such an
individual or family member of an individual who is a pregnant woman,
include genetic information of any fetus carried by such pregnant woman; and
(2) with respect to an individual or family member utilizing an assisted
reproductive technology, include genetic information of any embryo legally
held by the individual or family member.
Id.
72. Id. at § 2000ff(4)(C) (20012).
73. Abigail Lauren Perdue, Justifying GINA, 78 TENN, L. REV. 1051, 1065 (2011);
see also Jessica L. Roberts, The Genetic Information Nondiscrimination Act as an
Antidiscrimination Law, 86 NOTRE DAME L. REV. 597, 625 (2011) (explaining that the
ADA can be understood as retrospective in application, looking to existing discrimination
to justify protecting against future harm, while GINA is more forward looking in its
attempt to preempt discrimination before it becomes entrenched).
74. 42 U.S.C. §§ 2000ff-1(b)(1)-(6).
75. Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff-1(b)(1).
76. Id. at § 2000ff-1(b)(2).
77. Id. at § 2000ff-1(b)(3).
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not prohibited from purchasing commercially and publicly available
documents that contain family medical information of an employee.78 An
employer may also require genetic information from an employee if it is
used to genetically monitor the biological effects of toxic substances in the
workplace, provided the employer gives written notice and obtains a
voluntary and written authorization from the employee.79 Finally, employers
may conduct DNA analysis for law enforcement purposes or when necessary
to identify human remains.80	
  

IV. THE CASE FOR A BUSINESS NECESSITY EXCEPTION TO GINA
In response to the fearful environment created by the potential for genetic
discrimination and the possibility of stifling unprecedented scientific
discovery, Congress omitted a business necessity exception to GINA.81 In
fact, in a 2009 EEOC hearing on the proposed rule to implement the Act,
Jeremy Gruber of the National Council for Responsible Genetics echoed this
sentiment that informed the legislation, stating that, “over the course of
many years it was very difficult for even the best minds to come up with
ways or examples” where a job-related, business necessity exception would
be necessary.82 Congress, however, was too limited with its exceptions to
GINA and, like with the ADA,83 GINA would benefit from the addition of a
business necessity exception.84 In lieu of a general business necessity
exception, Congress should, at a minimum, adopt the ADA’s direct threat to
the health and safety of self or others standard.

	
  
78. Id. at § 2000ff-1(b)(4); see generally Family and Medical Leave Act of 1993,
Pub. L. No. 111-84, 123 Stat. 124.
79. 42 U.S.C. § 2000ff-1(b)(5).
80. Id. at § 2000ff-1(b)(6).
81. Notice of Proposed Rulemaking Implementation of Title II of the Genetic
Information Non-Discrimination Act of 2008 (Commission Meeting of February 25,
2009),
transcript
available
at:
http://www1.eeoc.gov//eeoc/meetings/2-2509/transcript.cfm?renderforprint=1 [hereinafter Notice of Proposed Rulemaking]. Jeremy
Gruber is President and Executive Director of the Council for Responsible Genetics. He
has worked extensively on the issue of genetic discrimination, including working closely
with members of Congress and their staff on the language of GINA as well as on strategy
and support. Further, he is a founding member of the Coalition for Genetic Fairness, a
group of 500 organizations that advocated on Capitol Hill for the passage of GINA.
Board of Directors and Emeriti, COUNCIL FOR RESPONSIBLE GENETICS, http://www.
councilforresponsiblegenetics.org/Help/Directors.aspx (last visited Dec.17, 2012).
82. Notice of Proposed Rulemaking, supra note 81.
83. Title VII of the Civil Rights Act of 1964 also has a business necessity exception,
applicable to disparate impact. 42 U.S.C. § 2000e-2(k).
84. See generally 42 U.S.C. § 12112(d)(4)(A) (2000).
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Situations do in fact exist where genetic testing by an employer could
prevent a threat to the health of an employee.85 Multiple situations arise
where a business necessity defense could be justified on this grounds.86 One
of the most dramatic situations implicated by the absence of a business
necessity/direct threat exception is where an employee’s health is
endangered by the inability to receive a genetic test (or by the fear of
offering a test that could be deemed a genetic test). As referenced
previously, this is a situation faced by employees of the State Department,
Peace Corp, USAID, and civilians in the DOD operating in malaria-infested
parts of the world. However, individuals such as these could avoid an
adverse reaction to a common anti-malaria medication if limited genetic
testing were permitted as part of a business necessity exception to GINA.87
A. G6PD Deficiency
G6PD deficiency is the most common enzyme deficiency in the world,
and “[a]pproximately 400 million people are affected worldwide.”88 This
deficiency occurs with more frequency throughout Asia, Africa, the
Mediterranean, and the Middle East.89 In the United States it is estimated
that ten percent of African American males are affected.90 The condition
primarily affects red blood cells, which are responsible for carrying oxygen
from the lungs to the rest of the body.91 A defect in the G6PD results in a
premature breakdown of these cells at a much faster rate than the body is
capable of replacing them.92
Though the carriers of this deficiency are often asymptomatic, in certain
instances acute hemolysis can occur.93 Hemolysis (or hemolytic anemia) is
characterized by the breakdown of the red blood cells94 and can cause
“paleness, yellowing of the skin and whites of the eyes (jaundice), dark

	
  
85. See generally Chevron USA Inc. v. Echazabal, 536 U.S. 73 (2002).
86. For example, there could be instances where taking a family medical history
could be important to evaluating an individual’s ability to safely perform a job.
87. Baruch & Hudson, supra note 6, at 438.
88. Jennifer E. Frank, Diagnosis and Management of G6PD Deficiency, 72 AM.
FAMILY PHYSICIAN 1277, 1277 (2005).
89. Id.
90. Id.
91. Glucose-6-phosphate Dehydrogenase Deficiency, GENETICS HOME REFERENCE,
NAT’L INSTS. HEALTH (last updated Aug. 18, 2014), http://ghr.nlm.nih.gov/condition
/glucose-6-phosphate-dehydrogenase-deficiency.
92. Id.
93. Frank, supra note 88, at 1277.
94. Hemolysis, MEDLINE PLUS, NAT’L INSTS. HEALTH, http://www.nlm.nih.gov/
medlineplus/ency/article/002372.htm (last updated Feb. 8, 2012).
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urine, fatigue, shortness of breath and a rapid heart rate.”95 While rarely
fatal, there are extreme cases where a severe reaction can necessitate a lifesaving blood transfusion.96 Differing types of gene mutations associated
with this condition dictate the level of deficiency and the resulting severity
of symptoms experienced by the individual.97 Adverse reactions within
carriers of this condition are often the result of exposure to certain oxidative
stressors, including infection, oxidative drugs, or fava beans.98 Generally,
“treatment is geared towards avoidances of these and other stressors.”99 An
example of an oxidative drug that may trigger a reaction in someone with
this condition is the common anti-malaria drug, primaquine.100 This drug, in
fact, has been identified by some sources as being the most common agent
leading to hemolysis in G6PD-deficient persons.101
B. G6PD Testing as Potential Genetic Discrimination
While no case has been litigated on the subject of whether G6PD testing is
a form of genetic discrimination, early in 2012 a complaint was filed in the
United States District Court for the Southern District of New York alleging
that the United States Peace Corps violated GINA when it based an
employment decision on the results of a G6PD test.102 The complainant,
Imoite Ipaalinyang Omulepu, applied for a Peace Corps Response Kavango
Basket Liaison position based in northern Namibia in March of 2011.103
Omulepu was ultimately offered a position as a Peace Corps Response
Volunteer (PCRV); however, his final acceptance was contingent upon
successful completion of all legal and medical clearances.104 Pursuant to the
provided instructions, the complainant completed the required medical

	
  
95. Frank, supra note 88, at 1277.
96. Id.
97. Id. (explaining that individuals who are homozygous for the deficiency typically
have more severe reactions that those who are heterozygous).
98. Id.
99. Id.
100. Murray, supra note 4. Primaquine, the brand name for primaquine phosphate, is
used with other medications to both prevent and treat malarial infections that are a result
of mosquito bites. Primaquine focuses on destroying the parasites that cause malaria.
Primaquine, MEDLINE PLUS, NAT’L INSTS. HEALTH, http://www.nlm.nih.gov/medlineplus/
druginfo/meds/a607037.html (last visited Apr. 20, 2014).
101. Id. G6PD deficiency was first discovered, in fact, out of an investigation of
cases of hemolytic anemia occurring in some individuals being treated for malaria with
the same class of drugs. Beutler, supra note 5, at 16.
102. Complaint, Omulepu v. United States Peace Corps, No. 1:12-cv-00988
(S.D.N.Y. Feb.7, 2012), ECF No. 2, available at 2012 WL 5215600.
103. Id. at 4.
104. Id. at 5.
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examination and tests, which included a screening for G6PD deficiency.105
Omulepu tested positive for the deficiency, both in the initial blood test and
a subsequent re-testing, which was undertaken to rule out the possibility that
the initial results indicated a false positive.106
A nurse employed by the Peace Corps informed the complainant that the
agency had implemented a new policy in 2008 that stated individuals who
tested positive for the G6PD deficiency were ineligible to serve in malariaendemic countries.107 Based on the two sets of test results, the Peace Corps
Pre-Service Review Board was unable to clear Omulepu for service in
Namibia.108 The Board offered the complainant the opportunity for appeal,
but despite a letter from a hematologist stating that Omulepu was not at
significant risk for “significant primaquine induced hemolysis,” the Board
denied his appeal.109 He was not, however, deemed ineligible to work for
the Peace Corps and was informed he had the opportunity to serve as a
PCRV in areas outside malaria zones.110 Omulepu claimed that the Peace
Corps violated GINA, in part, by allowing its employment decision to be
based on the results of a genetic test.111 He further claimed that as a result of
this action, he suffered a lack of employment opportunities while his
confidence in seeking a career path on the African continent was
diminished.112
In its response to the complainant’s filing, the Peace Corps asserted that
its guideline for G6PD deficiency was informed by recommendations made
by the Center for Disease Control and Prevention (CDC).113 It cited CDC
literature indicating that primaquine is contraindicated in people with the
deficiency, and accordingly, the Peace Corps will not place such people in a
malarial area where primaquine is required due to the health concerns that
may arise.114 In addition, the Peace Corps contended that it did not obtain

	
  
105. Id.
106. Id. at 5-6.
107. Id. at 6.
108. Complaint at 6, Omulepu v. United States Peace Corps, No. 1:12-cv-00988
(S.D.N.Y. Feb.7, 2012), ECF No. 2, available at 2012 WL 5215600.
109. Id. at 7.
110. Id.
111. Id. at 10. The plaintiff, who represented himself in this matter, demonstrated an
imprecise understanding of the statute, mistakenly outlining that GINA was violated, in
part, by what he perceived as the Peace Corps making the assumption that testing positive
for the genetic variant was a definite diagnosis of the disease. Id.
112. Id. at 2.
113. Id. at 3.
114. Complaint at 3, Omulepu v. United States Peace Corps, No. 1:12-cv-00988
(S.D.N.Y. Feb.7, 2012), ECF No. 2, available at 2012 WL 5215600. In speaking for the
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any genetic information from Omulepu, but rather only required a blood test
to determine whether there was a deficiency in the G6PD enzyme.115 The
agency further denied use of the test as the basis of its employment decision,
as Omulepu was offered the opportunity to pursue alternative PCV positions
outside malarial zones.116 Finally, the Peace Corps maintained that, if GINA
were to prohibit the use of such a blood test, the agency would be put in a
position in which it may place PCVs in areas where there is an increased risk
of serious health consequences.117 Accordingly, the Peace Corps asserted
that placing volunteers in malaria-endemic countries without the G6PD
testing would be acting both irresponsibly and medically unethically.118
This case was never brought to trial; a Stipulation and Order of Settlement
and Dismissal was filed on September 4, 2012.119 According to the terms of
the settlement, the action was dismissed with prejudice against the Peace
Corp “without costs or disbursements.”120 Furthermore, the terms mandated
that as soon as practicable after the date of the Order, the Agency shall use
its “best efforts” in order to place Omulepu in a PCV position.121
Significantly, the settlement called for the Peace Corps to place the
complainant in a malarial region, despite his G6PD deficiency.122 While
settlement of the case prevented a ruling on whether the Peace Corps’
actions constituted genetic discrimination under GINA, the settlement may
very well lead to more employers being forced to place employees in harm’s
way, despite their reasoned assessment of the dangers of the situation.
C. G6PD Testing and the Military
The lengthy amount of time that the United States has recently spent in
both Iraq and Afghanistan, and the resulting strain on our military, has the

	
  
Peace Corps, Dr. Barry Simon asserted that it would be a violation of medical ethics to
administer Primaquine to an individual such as the complainant.
115. Id. at 8. This Note takes no position on the legal question of whether a G6PD
test is a genetic test under GINA (on which there is no case law or other legal guidance).
116. Id. at 9.
117. Id.
118. Id.
119. Stipulation and Order of Dismissal, Omulepu v. United States Peace Corps, No.
1:12-cv-00988 (S.D.N.Y. Sept. 14, 2012) (on file with author).
120. Id.
121. Id.
122. Id. The order stipulates, however, that it does not constitute an admission of
liability or fault of any party, nor does it constitute an admission of liability or fault on
behalf of any of their departments, agencies, offices, agents, officials, or employees. Id.
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DOD looking to civilian employees to fill in the manpower gaps.123
Currently, it is DOD policy to rely on a mix of “capable military members
and DoD civilian employees to meet DOD global national security mission”
needs.124 DOD identifies safeguarding the health of its deployed civilian
employees as a matter of serious concern, and requires such employees to
undergo an annual medical assessment to determine eligibility for worldwide
deployment.125 While GINA’s restrictions do not apply to uniformed
members of the military, its regulations still apply to DOD civilian
employees.126
As explained in a 2006 seminar focusing on genetics perspectives on
policy, the members of the military are thought to require “special
[consideration] because they face ‘unusual occupational health challenges,’”
due to their assignment to a vast range of jobs in a vast range of
environments.127 It is standard for the military to collect DNA samples for
identification purposes should a service member die in battle.128 A positive
result for a genetic disorder is noted on a soldier’s medical records and is
taken into consideration for decisions regarding assignments.129 Particularly
relevant to this case, U.S. Armed Forces routinely test for G6PD deficiency
to ensure the safety of the uniformed personnel, making the deliberate
choice to keep those who are G6PD deficient out of malarial zones or, in the

	
  
123. DEP’T OF DEF., DIRECTIVE (NO. 1404.10), DOD CIVILIAN EXPEDITIONARY
WORKFORCE, (Jan. 23, 2009), http://www.dtic.mil/whs/directives/corres/pdf/140410p.pdf.
124. Id.
125. Id.
126. Baruch & Hudson, supra note 6, at 438.
127. Genes in Uniform: Don’t Test, Don’t Tell, Genetic Perspectives on Pol’y
Seminar, Jan. 10, 2006, available at http://www.dnapolicy.org/news.past.php?action
=detail&past_event_id=25 (last visited Oct. 14, 2012). Panelists included Susannah
Baruch, senior policy analyst at The Genetics and Public Policy Center; Dr. Mark Nunes,
a former military physician who is now a clinical and laboratory geneticist at both
Children’s Hospital in Columbus and at Ohio State University; and Jay Platt, an author,
coach, motivation speaker and formerly a United States Marine Corps drill instructor.
While representatives of the Department of Defense were invited, they declined to
participate. Id.
128. Patricia A. Ham, et al., An Army of Suspects: The History and Constitutionality
of the U.S. Military’s DNA Repository and its Access for Law Enforcement Purposes,
2003 ARMY L. 1, 1 (July/Aug. 2003); see also DEP’T OF DEF., INSTRUCTION (NO.
5154.30), ARMED FORCES INSTITUTE OF PATHOLOGY OPERATIONS (Mar. 18, 2003),
http://www.dtic.mil/whs/directives/corres/pdf/515430p.pdf.
129. Baruch, supra note 6, at 438; E-mail from Catherine Takacs Witkop, MD, MPH,
Chief, Preventative Medicine, United States Air Force to Alyson Horn, JD Candidate,
Catholic University Columbus School of Law (Oct. 1, 2013, 09:21 AM) (on file with the
author) [hereinafter Witkop Email].
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alternative, to provide them with an alternate anti-malarial drug.130 This is
particularly noteworthy because of the prevalence of malaria in
Afghanistan.131 If the G6PD test were deemed a genetic test, then deployed
civilians would lack the same health protections afforded to uniform
personnel.
D. An Argument for the Amendment of GINA
Jeremy Gruber, an influential voice behind the scenes of the drafting of
the language of GINA, testified that experts could think of no examples that
warranted a business necessity exception.132 This, however, simply reflects
a lack of consideration of the reality faced by those who work outside the
traditional workplace. Civilian employees of DOD, members of the State
Department, and those employed by the Peace Corps, among others, often
work in environments far removed from the stereotypical office setting and,
as a result, face a range of different and difficult challenges. The Peace
Corps expressed legitimate concerns, informed in part by guidance provided
by the CDC, when it initially refused to place Omulepu in a malarial region
to prevent a potential negative reaction to the use of primaquine.133 Because
GINA contains no business necessity exception, the Peace Corps was forced
into entering a settlement—the type of dilemma similar employers will
surely face in the future.134 Barring legislative change, more and more
employers will find themselves in a position where, against their better
judgment, they will knowingly place employees in harm’s way.
A business necessity exception amendment to GINA, similar to the
business necessity exception to the ADA, would help alleviate the potential
threats faced by employees in non-traditional work environments. While the
business necessity exception to the ADA covers a “direct threat” to one’s
self or others that arises out of a condition with physical manifestations, the
exception to GINA would be for genetic conditions, like G6PD deficiency,
which may manifest as a direct result of stressors or other conditions in the
workplace.135 To prevent abuse of discretion, it is sound policy to require

	
  
130. Baruch, supra note 6, at 438.
131. Malaria is found from April through December in areas of Afghanistan at
altitudes above 6,500 feet. See CDC Malaria Map Application, CENTERS FOR DISEASE
CONTROL & PREVENTION, http://www.cdc.gov/malaria/map/index.html (last visited Apr.
15, 2014).
132. Notice Proposed Rulemaking, supra note 81.
133. Complaint, Omulepu v. U.S. Peace Corps, No. 1:12-cv-00988 (S.D.N.Y. Feb.7,
2012), ECF No. 2, available at 2012 WL 5215600.
134. Stipulation and Order of Dismissal, Omulepu v. United States Peace Corps, No.
1:12-cv-00988 (S.D.N.Y. Sept. 14, 2012).
135. 42 U.S.C. § 12113(b).
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that the employer have the burden of proving that no reasonable
accommodation to ensure employee safety can be made prior to denying an
employee or applicant a position based on a genetic condition. Any business
necessity exception that arises out of this proposed change should be
extremely limited and carefully considered to prevent abuse as society
continues to learn more about human genetics. However, based on what we
now know, such an exception has the ability to make work safer for those in
both traditional and non-traditional workplace environments.
CONCLUSION
While uniformed members of the armed forces who test positive for
G6PD deficiency are either not assigned to locations that would require them
to take malaria medication or are given an anti-malarial medication other
than primaquine,136 the G6PD status of Peace Corp, State Department, and
DOD civilians, who are often in malaria-infested locations comparable to
their uniformed colleagues, potentially cannot be factored into decisions
about assignments under GINA. This disparate treatment has the potential
to pose a direct threat to the health of these civilian employees. The Peace
Corps specifically recognized the potential dangers of assigning G6PD
deficient employees to malarial areas, stating in its response to Imoite
Ipaalinyang Omulepu’s complaint that sending such a person to a location
where primaquine is required would be not just irresponsible, but medically
unethical.137 Though the Peace Corps maintains that their required blood
test is not a request for genetic information,138 the Agency agreed in
settlement to place Omulepu in a malaria-endemic region,139 going against
what it believed to be medically ethical. By pushing forward with this
complaint, Omulepu is placing himself in potentially serious danger (a direct
threat-to-self), in the form of an adverse reaction to primaquine as a result of
his G6PD deficiency.140
The facts therefore suggest that situations arise where a business necessity
exception, or a direct threat to the health or safety of the employee or others
rule similar to that found under the ADA, is warranted for the protection of
individuals in the workplace. If such testing were permitted in limited
circumstances, such as under the conditions faced by the federal employees
assigned to work in malaria-infested regions like Afghanistan and sub-

	
  
136. Baruch & Hudson, supra note 6, at 439; Witcop Email, supra note 129.
137. Complaint, supra note 133, at 9.
138. Id.
139. Stipulation and Order of Dismissal, Omulepu v. United States Peace Corps, No.
1:12-cv-00988 (S.D.N.Y. Sept. 14, 2012).
140. See generally Murray, supra note 4, at 905.
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Saharan Africa, the threat of an adverse reaction to a common medication
like primaquine could largely be avoided by military and civilians alike.
Clearly these atypical workplaces were not contemplated when GINA was
drafted.
While critics may posit that such an exception is not required based on the
reality of the workplace, the example faced by employees of the State
Department, Peace Corps and civilians in the DOD sent to malarial regions
suggests differently. Looking more broadly, the case of G6PD deficiency is
only one such example where a business necessity exception could benefit
both employer and employee. Recognizing that situations would need to be
evaluated carefully to prevent discrimination, and similar to the ADA
exception, the employer should have the burden of demonstrating an
adequate justification for the need for genetic testing.141 Thus, amending
GINA to have the flexibility of a business necessity exception is sound
public policy for the safety of workers.
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